
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
Avita Medical has shown promising financial trends, including an 11% year-over-year revenue increase, reaching $71.6 million for the full year, and an improvement in cash usage that decreased sequentially to approximately $5.1 million. The company's management has set revenue guidance for 2026 between $80 million and $85 million, indicating expectations of growth in the range of 12% to 19% driven by strategic initiatives and deeper market penetration. Additionally, Avita's recent refinancing of debt has bolstered its balance sheet, enhancing its capacity to support sustained growth and operational execution in the coming years.
Bears say
Avita Medical reported a net loss of $11.6 million, or $0.38 per share, which reflects a slight improvement from the previous year's loss of $11.6 million, or $0.44 per share; however, this does not indicate a strong financial performance. The company’s revenue structure is concerning, with only approximately $3.97 million guaranteed over a 10-year term, which highlights a significant reliance on optional procurement that could create revenue uncertainty. This leads to a negative outlook, as the reliance on a single product, along with back-end loaded revenue from a government preparedness contract, undermines the company's overall financial stability and growth potential.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares